Randomized phase ll study of mFOLFOX6 + bevacizumab or mFOLFOX6+cetuximab in liver only metastasis from KRAS wild type colorectal cancer
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms ATOM
- 09 Jul 2019 Safety and efficacy results published in the British Journal of Cancer.
- 31 Aug 2018 Biomarkers information updated
- 20 Jan 2018 Primary endpoint (Progression-free survival) has been met as per the results presented at the 2018 Gastrointestinal Cancers Symposium.